{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:56:22Z","timestamp":1756810582767,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10147-021-01883-2","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T10:02:47Z","timestamp":1616580167000},"page":"1130-1138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-5820","authenticated-orcid":false,"given":"Ken","family":"Ishitani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Isoai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Torii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Soneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiju","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Hanafusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"1883_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-2001-10707","volume":"39","author":"D Zaak","year":"2001","unstructured":"Zaak D, Paquet KJ, Kuhn R (2001) Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol 39:5\u201310. https:\/\/doi.org\/10.1055\/s-2001-10707","journal-title":"Z Gastroenterol"},{"key":"1883_CR2","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.4161\/cc.29951","volume":"13","author":"M Cohen","year":"2014","unstructured":"Cohen M, Petignat P (2014) The bright side of ascites in ovarian cancer. Cell Cycle 13:2319. https:\/\/doi.org\/10.4161\/cc.29951","journal-title":"Cell Cycle"},{"key":"1883_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1172\/JCI101037","volume":"18","author":"HA Davis","year":"1939","unstructured":"Davis HA, Blalock JF (1939) Autologous and homologous transfusion of human ascitic fluid. J Clin Invest 18:219\u2013224. https:\/\/doi.org\/10.1172\/JCI101037","journal-title":"J Clin Invest"},{"key":"1883_CR4","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10147-014-0750-y","volume":"20","author":"T Ito","year":"2015","unstructured":"Ito T, Hanafusa N, Iwase S et al (2015) Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol 20:623\u2013628. https:\/\/doi.org\/10.1007\/s10147-014-0750-y","journal-title":"Int J Clin Oncol"},{"key":"1883_CR5","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.3892\/mco.2014.335","volume":"2","author":"O Maeda","year":"2014","unstructured":"Maeda O, Ando T, Ishiguro K et al (2014) Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol 2:1103\u20131106. https:\/\/doi.org\/10.3892\/mco.2014.335","journal-title":"Mol Clin Oncol"},{"key":"1883_CR6","first-page":"301","volume":"35","author":"S Togami","year":"2014","unstructured":"Togami S, Hori S, Kamio M et al (2014) Clinical usefulness of concentrated ascites reinfusion therapy (CART) for gynecological cancer patients with refractory massive ascites due to cancerous peritonitis. Eur J Gynaecol Oncol 35:301\u2013303","journal-title":"Eur J Gynaecol Oncol"},{"key":"1883_CR7","first-page":"2353","volume":"32","author":"T Ueda","year":"2012","unstructured":"Ueda T, Maehara M, Takahashi Y et al (2012) Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res 32:2353\u20132357","journal-title":"Anticancer Res"},{"key":"1883_CR8","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1111\/jog.12763","volume":"41","author":"L Wang","year":"2015","unstructured":"Wang L, Okubo T, Shinsaka M et al (2015) Efficacy and safety of cell-free and concentrated ascites reinfusion therapy (CART) in gynecologic cancer patients with a large volume of ascites. J Obstet Gynaecol Res 41:1614\u20131620. https:\/\/doi.org\/10.1111\/jog.12763","journal-title":"J Obstet Gynaecol Res"},{"key":"1883_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/1744-9987.12560","volume":"21","author":"Y Yamada","year":"2017","unstructured":"Yamada Y, Yamaguchi A, Harada M et al (2017) Protein concentration of refractory ascites in cancer patients is reflected by the presence and severity of peritoneal and liver metastasis. Ther Apher Dial 21:263\u2013269. https:\/\/doi.org\/10.1111\/1744-9987.12560","journal-title":"Ther Apher Dial"},{"key":"1883_CR10","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.ejso.2015.04.013","volume":"41","author":"H Yamaguchi","year":"2015","unstructured":"Yamaguchi H, Kitayama J, Emoto S et al (2015) Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1. Eur J Surg Oncol 41:875\u2013880. https:\/\/doi.org\/10.1016\/j.ejso.2015.04.013","journal-title":"Eur J Surg Oncol"},{"key":"1883_CR11","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00520-017-3980-5","volume":"26","author":"R Hanada","year":"2018","unstructured":"Hanada R, Yokomichi N, Kato C et al (2018) Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: A concept-proof study. Support Care Cancer 26:1489\u20131497. https:\/\/doi.org\/10.1007\/s00520-017-3980-5","journal-title":"Support Care Cancer"},{"key":"1883_CR12","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1038\/s41598-019-46774-9","volume":"9","author":"Y Yamada","year":"2019","unstructured":"Yamada Y, Inui K, Hara Y et al (2019) Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study. Sci Rep 9:10195. https:\/\/doi.org\/10.1038\/s41598-019-46774-9","journal-title":"Sci Rep"},{"key":"1883_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdg013","volume":"14","author":"J Alexandre","year":"2003","unstructured":"Alexandre J, Gross-Goupil M, Falissard B et al (2003) Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe hematological toxicity following chemotherapy. Ann Oncol 14:36\u201341","journal-title":"Ann Oncol"},{"key":"1883_CR14","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","volume":"12","author":"C Kloft","year":"2006","unstructured":"Kloft C, Wallin J, Henningsson A et al (2006) Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 12:5481\u20135490. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0815","journal-title":"Clin Cancer Res"},{"key":"1883_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.1996.14.1.257","volume":"14","author":"SP Joel","year":"1996","unstructured":"Joel SP, Shah R, Clark PI et al (1996) Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 14:257\u2013267. https:\/\/doi.org\/10.1200\/JCO.1996.14.1.257","journal-title":"J Clin Oncol"},{"key":"1883_CR16","doi-asserted-by":"publisher","first-page":"e0177303","DOI":"10.1371\/journal.pone.0177303","volume":"12","author":"N Hanafusa","year":"2017","unstructured":"Hanafusa N, Isoai A, Ishihara T et al (2017) Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS ONE 12:e0177303. https:\/\/doi.org\/10.1371\/journal.pone.0177303","journal-title":"PLoS ONE"},{"key":"1883_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/1744-9987.12049","volume":"18","author":"T Ito","year":"2014","unstructured":"Ito T, Hanafusa N, Fukui M et al (2014) Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites. Ther Apher Dial 18:87\u201392. https:\/\/doi.org\/10.1111\/1744-9987.12049","journal-title":"Ther Apher Dial"},{"key":"1883_CR18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649\u2013655","journal-title":"Am J Clin Oncol"},{"key":"1883_CR19","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.2169\/internalmedicine.3091-19","volume":"58","author":"M Iwasa","year":"2019","unstructured":"Iwasa M, Ishihara T, Kato M et al (2019) Cell-free and concentrated ascites reinfusion therapy for refractory ascites in cirrhosis in post-marketing surveillance and the role of tolvaptan. Intern Med 58:3069\u20133075. https:\/\/doi.org\/10.2169\/internalmedicine.3091-19","journal-title":"Intern Med"},{"key":"1883_CR20","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1007\/s00520-020-05401-4","volume":"28","author":"Y Nagata","year":"2020","unstructured":"Nagata Y, Kato K, Miyamoto T et al (2020) Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in gastrointestinal cancer patients with massive ascites treated with systemic chemotherapy. Support Care Cancer 28:5861\u20135869. https:\/\/doi.org\/10.1007\/s00520-020-05401-4","journal-title":"Support Care Cancer"},{"key":"1883_CR21","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.21873\/anticanres.12732","volume":"38","author":"Y Abe","year":"2018","unstructured":"Abe Y, Kobayashi H, Akizawa Y et al (2018) Possible application of ascites-infiltrating gamma-Delta T cells for adoptive immunotherapy. Anticancer Res 38:4327\u20134331. https:\/\/doi.org\/10.21873\/anticanres.12732","journal-title":"Anticancer Res"},{"key":"1883_CR22","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IGC.0000000000001263","volume":"28","author":"JM Jennifer","year":"2012","unstructured":"Jennifer JM, Henrik L, Berit JM et al (2012) International study of primary mucinous ovarian carcinomas managed at tertiary medical centers. Int J Gynecol Cancer 28:915\u2013924. https:\/\/doi.org\/10.1097\/IGC.0000000000001263","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-021-01883-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-021-01883-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T09:18:24Z","timestamp":1621415904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-021-01883-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1883"],"URL":"https:\/\/doi.org\/10.1007\/s10147-021-01883-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"type":"print","value":"1341-9625"},{"type":"electronic","value":"1437-7772"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"31 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}